WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 466152
CAS#: 1263402-76-1
Description: ZYDPLA1 is a novel next generation orally active DPP-4 inhibitor to treat Type 2 Diabetes.
MedKoo Cat#: 466152
Name: ZYDPLA1
CAS#: 1263402-76-1
Chemical Formula: C24H21N5O5S
Exact Mass: 491.1263
Molecular Weight: 491.522
Elemental Analysis: C, 58.65; H, 4.31; N, 14.25; O, 16.27; S, 6.52
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: ZYDPLA1; ZYDPLA 1; ZYDPLA-1;
IUPAC/Chemical Name: (S)-3-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy)-5-((1-methyl-2-oxopyrrolidin-3-yl)oxy)-N-(thiazol-2-yl)benzamide
InChi Key: AOZKMKQCNOIYGR-FQEVSTJZSA-N
InChi Code: InChI=1S/C24H21N5O5S/c1-14-27-28-22(32-14)15-3-5-17(6-4-15)33-18-11-16(21(30)26-24-25-8-10-35-24)12-19(13-18)34-20-7-9-29(2)23(20)31/h3-6,8,10-13,20H,7,9H2,1-2H3,(H,25,26,30)/t20-/m0/s1
SMILES Code: O=C(NC1=NC=CS1)C2=CC(O[C@@H]3C(N(C)CC3)=O)=CC(OC4=CC=C(C5=NN=C(C)O5)C=C4)=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 491.522 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Giri P, Patel N, Patel B, Patel H, Bahekar R, Srinivas NR, Patel PR, Desai R. Sensitive and specific LC-ESI-MS/MS method for determination of ZYDPLA1, a novel long-acting dipeptidyl peptidase 4 inhibitor in rat plasma: An application for toxicokinetic study in rats. Biomed Chromatogr. 2017 Nov;31(11). doi: 10.1002/bmc.3984. Epub 2017 May 29. PMID: 28370279.
2: Patel H, Joharapurkar AA, Bahekar R, Patel P, Kshirsagar SG, Modi N, Ghoghari A, Patel VJ, Jain MR, Srinivas NR, Patel PR, Desai RC. Is the Inhibition of Dipeptidyl Peptidase-4 (DDP-4) Enzyme Route Dependent and/or Driven by High Peak Concentration?- Seeking Answers with ZYDPLA1, a Novel Long Acting DPP-4 Inhibitor, in a Rodent Model. Drug Res (Stuttg). 2017 Apr;67(4):223-227. doi: 10.1055/s-0042-122776. Epub 2017 Feb 3. PMID: 28158894.
3: Jain MR, Joharapurkar AA, Bahekar RH, Patel H, Jadav P, Kshirsagar SG, Patel VJ, Patel KN, Ramanathan VK, Patel PR, Desai RC. Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor. J Diabetes. 2015 Sep;7(5):708-17. doi: 10.1111/1753-0407.12233. Epub 2014 Dec 17. PMID: 25327540.
